# ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer

Source: https://onco.cc/trials/nct06714357/  
OnCo record `nct06714357` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fOLFIRI (5-FU, leucovorin, irinotecan) and panitumumab in colorectal cancer, run by National Cancer Institute, Naples, now recruiting.

## Summary

ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer is a phase 2, randomised interventional study registered as NCT06714357 by National Cancer Institute, Naples, with a registry enrolment figure of 130 participants, started 2025-03-12 and due to reach its primary completion in 2026-12-20. Interventions recorded: irinotecan; panitumumab; Valproic Acid (VPA). Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Study Part 1 - Progression Free Survival rate at 16 weeks in the two arms.. Colorectal eligibility wording from the registry: "Histologically proven of colorectal adenocarcinoma". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: VICTORIA
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06714357
- Phase: 2
- Setting: Randomized Phase 2 Study of Valproic Acid Combined With Rechallenge Anti-EGFR Based Regimen Regimens in Pretreated Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer - VICTORIA Trial
- Sponsor: National Cancer Institute, Naples
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT06714357: https://clinicaltrials.gov/study/NCT06714357

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [Panitumumab](https://onco.cc/drugs/panitumumab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06714357.json